HUBS finds itself in an unusual spot this week: a wave of analyst upgrades to price targets landing on a stock that just fell nearly 10% in five sessions.
The Street activity this week was striking in both its volume and its direction. Multiple firms moved targets higher on September 18 and 21, even as the stock was selling off. UBS lifted its target from $250 to $290 while reiterating Buy. RBC Capital held firm at $300 with an Outperform. Truist raised to $275 from $230, also a Buy. BMO Capital moved its Market Perform target from $215 to $250. That cluster of upward revisions arrived while HUBS was trading well below all of them — the stock closed Tuesday at $217.88, with the consensus mean target now sitting near $250. The lone dissenter in the batch was TD Cowen, which cut its Hold target from $285 to $260, citing a more cautious near-term view. The overall picture is a Street that sees the post-earnings selloff as an overshoot, even if conviction is uneven — 19 analysts hold a Hold rating, and the consensus remains a hold rather than a buy.
The context matters here. The previous earnings note published here on September 14 flagged that short sellers were not pressing their advantage into the September 17 print, with SI collapsed from over 5.3 million shares to around 2.7 million. That print arrived and took another 8.6% off the stock in a single day — adding to August's brutal 18.7% one-day collapse. HUBS is now down roughly 44% year-to-date. What's changed since the September 14 note is that SI has partially rebuilt. Short interest climbed about 13% over the past week to nearly 5.95% of free float, reversing some of the earlier contraction. That's a meaningful move. Shorts that stepped aside into the print appear to be rebuilding positions now that the stock has reset lower.
The borrow market tells a more nuanced story, though. Availability remains extraordinarily loose at roughly 2,800% of shares already lent out — down sharply from above 4,400% a week ago, but still far above any level that would signal squeeze pressure. Cost to borrow has actually eased, falling about 22% over the week to just 0.30% annually. The tightening in availability reflects the SI rebuild, but the absolute level means there is ample capacity for more shorting if sentiment deteriorates further. Options positioning is mildly defensive — the put/call ratio at 1.18 is slightly above its 20-day average of 1.15 — but the z-score of under 1 rules out any panic hedging. The borrow market and options combined read as cautious rather than alarmed.
One ownership detail worth noting: director Gerald Dischler made an open-market purchase of 925 shares at $215.93 on August 10 — a discretionary buy, not under a 10b5-1 plan. That purchase came in the aftermath of August's catastrophic single-session drop and sits below the current price. Director Brian Halligan, by contrast, has been executing scheduled 10b5-1 sales, offloading 8,500 shares in both August and September. The 90-day net insider position is negative at around -25,000 shares and approximately -$5.8 million in value, though the bulk of that reflects tax-withholding transactions from September 1 rather than discretionary selling. Halligan's planned sales are routine under a pre-arranged programme and carry limited signal. Dischler's discretionary purchase is the more interesting data point.
Valuation multiples have compressed alongside the price. The P/E has fallen about 2.1x over the past 30 days, and the P/B ratio has shed roughly 0.74x over the same period. At current levels the stock trades well below the consensus mean target, but forward earnings growth ranks in only the 14th percentile of the universe — the Street is still waiting for the growth re-acceleration narrative to materialise. The short score of 39.5 has crept higher over the past week from 37, moving in the direction of more short pressure but still well within the lower half of the universe. Peers had a rough week too: MNDY fell nearly 10%, KVYO shed 6.5%, and WK lost 6.7% — suggesting this is partly sector-wide software rotation rather than HUBS-specific selling, though HUBS's year-to-date drawdown remains far steeper than any of them.
The next earnings event is November 4. Between now and then, the key tension is whether the analyst target upgrades reflect genuine conviction in a recovery or simply catch-up adjustments after targets lagged the selloff — and whether the partial SI rebuild accelerates if the stock fails to stabilise above $210.
See the live data behind this article on ORTEX.
Open HUBS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
